Megan Ingham

• BSc Hons Pharmacology
• The use of specific-molecule inhibitors in the treatment of t(8;21) positive acute myeloid leukaemia

Although many types of leukaemia have seen survival rates rise in recent years, this is only through refinement of treatment protocols with mainly chemotherapeutic agents which have barely changed for decades.  These treatments come with distinct acute and chronic side effects that can be permanently disabling for survivors, hence there is a significant need to utilise a range of targeted treatments for specific types of leukaemia in order to increase survival and minimise side effects.  This project seeks to do just this in a type of leukaemia called t(8;21) AML using information from advanced genetic analysis.

Project Supervisor: Professor Olaf Heidenreich, Northern Institute for Cancer Research

Funding Source: Newcastle University